Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How will immune tolerance protocols affect self-sufficiency goals?

H H Brackmann1

  • 1Haemophilia Centre, University of Bonn, Germany.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|December 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetic properties of two factor VIII concentrates with single and double viral inactivation.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Long-term surveillance for human anti-murine antibodies of a group of haemophiliacs treated only with immunoaffinity-purified FVIII concentrates.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Massive factor-VIII infusion in Haemophiliac with factor-VIII inhibitor, high responder. 1977.

Haemophilia : the official journal of the World Federation of Hemophilia·2010
Same author

The relevance of the bleeding severity in the treatment of acquired haemophilia - an update of a single-centre experience with 67 patients.

Haemophilia : the official journal of the World Federation of Hemophilia·2008
Same author

Successful pain treatment in arthropathic lower extremities by acupuncture in haemophilia patients.

Haemophilia : the official journal of the World Federation of Hemophilia·2006
Same author

[The modified Bonn Malmö protocol (MBMP) in the treatment of acquired haemophilia A].

Deutsche medizinische Wochenschrift (1946)·2006
Same journal

Pampiniform venous plexus thrombosis in a 37 years-old male patient with severe thrombocytosis: a multifactorial aetiology.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

PROS1 Cys475Tyr mutation associated with a type III protein S deficiency pattern.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Dynamic microclot profiling: thromboelastography advances precision management in long COVID and myalgic encephalomyelitis/chronic fatigue syndrome.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Genetic characterization of Glanzmann thrombasthenia: insights from novel igta2b mutations in a Tunisian patient cohort.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Uterine fibroids as an underrecognized risk factor for venous thromboembolism: a narrative review.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

SEER sonorheometry enhances fibrinolysis detection during liver transplantation with heparin.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
See all related articles

Immune tolerance therapy for haemophilia is costly but improves quality of life. Early treatment reduces the need for factor VIII concentrate, enhancing patient outcomes.

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Haemophilia treatment involves managing factor deficiencies.
  • Inhibitor development is a significant complication in haemophilia management.
  • Immune tolerance therapy (ITT) is a treatment option for haemophilia inhibitors.

Observation:

  • ITT is an expensive but effective treatment for haemophilia inhibitors.
  • Early initiation of ITT can lead to better long-term outcomes.
  • ITT may reduce the lifelong requirement for clotting factor concentrates.

Findings:

  • Immune tolerance therapy can lead to an increased lifespan for haemophilia patients.
  • Successful ITT improves the quality of life for individuals with haemophilia.
  • Early intervention with ITT can decrease the overall need for factor VIII concentrate.

Related Experiment Videos

Implications:

  • Early ITT commencement is crucial for optimizing haemophilia care.
  • Reducing reliance on factor concentrates through ITT offers significant patient benefits.
  • Further research into cost-effectiveness and long-term efficacy of ITT is warranted.